InvestSMART

Alexium International Group Limited (ASX: AJX) - Announcements

- Current share price for AJX : $0.007

ASX company news and announcements for Alexium International Group Limited (AJX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alexium International Group Limited (AJX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alexium International Group Limited (AJX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alexium International Group Limited (AJX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$22 PolyCotten Achieves Milestone for Revenues By Years End 22 Oct 2013 10:10AM $0.145 $0.007 fallen by 95.17%
$22 FR Treatment Successfully Transitions into Production 14 Oct 2013 10:06AM $0.115 $0.007 fallen by 93.91%
$22 Alexium Validates CleanShell ChemBio With Good Results 2 Oct 2013 10:18AM $0.125 $0.007 fallen by 94.40%
$22 Alexium Commences Testing on Cleanshell for US Air Force 10 Sep 2013 10:03AM $0.115 $0.007 fallen by 93.91%
$22 Aleixum to Commence Nycolon Production Trials. 2 Sep 2013 10:06AM $0.125 $0.007 fallen by 94.40%
$22 Appendix 4E 30 Aug 2013 6:14PM $0.115 $0.007 fallen by 93.91%
$22 INDEPENDENT LABORATORY CERTIFY ASCALON PERFORMANCE 12 Aug 2013 10:12AM $0.125 $0.007 fallen by 94.40%
$22 Market Update On Line Trails And Produce Scale Up Process. 5 Aug 2013 10:06AM $0.130 $0.007 fallen by 94.62%
$22 Appendix 4C - quarterly 30 Jul 2013 10:46AM $0.115 $0.007 fallen by 93.91%
$22 PLACEMENT TO SOPHISTICATED INVESTORS 29 Jul 2013 9:58AM $0.115 $0.007 fallen by 93.91%
$22 Alexium Advances To Next Stage Production Trail 15 Jul 2013 10:05AM $0.110 $0.007 fallen by 93.64%
$22 ALEXIUM SETS SCHEDULE FOR PRODUCTION TRIALS OF NYCOLON 10 Jul 2013 10:06AM $0.100 $0.007 fallen by 93%
$22 AJX Receives Grant For Commercialisation of FR Treatments 8 Jul 2013 10:09AM $0.090 $0.007 fallen by 92.22%
$22 TECHNOLOGY BREAKTHROUGH Alexium extends FR technology 1 Jul 2013 10:22AM $0.125 $0.007 fallen by 94.40%
$22 Alexium Commences Line Trial Production Run at Duro 24 Jun 2013 10:08AM $0.120 $0.007 fallen by 94.17%
$22 Alexium Rolls Out Samples To European Customers 6 Jun 2013 10:06AM $0.096 $0.007 fallen by 92.71%
$22 Alexium Engage Chemical Toll Manufacturer 27 May 2013 10:08AM $0.090 $0.007 fallen by 92.22%
$22 Alexium Company, Market and Product Development Update 20 May 2013 10:14AM $0.085 $0.007 fallen by 91.76%
$22 TECHNICAL BREAK-THROUGH ON FR NEW TRADEMARK NYCOLON 2 May 2013 10:07AM $0.080 $0.007 fallen by 91.25%
$22 Appendix 4C - Quarterly 30 Apr 2013 3:36PM $0.074 $0.007 fallen by 90.54%
$22 Alexium Commences US Marine Work 24 Apr 2013 9:47AM $0.074 $0.007 fallen by 90.54%
$22 Alexium Achieves Revenue Growth 15 Apr 2013 10:08AM $0.074 $0.007 fallen by 90.54%
$22 Placement to Sophisticated Investors 12 Apr 2013 9:49AM $0.070 $0.007 fallen by 90%
$22 Trading Halt 9 Apr 2013 5:46PM $0.070 $0.007 fallen by 90%
$22 Alexium Wins Contract Award to Supply US Marine Corps 4 Apr 2013 10:13AM $0.072 $0.007 fallen by 90.28%

751 - 775 of 842 results

Page 31 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.